A-770041 - CAS 869748-10-7
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
A-770041
Catalog Number:
869748-10-7
CAS Number:
869748-10-7
Description:
A-770041 is an selective and orally bioavailable pyrazolo[3,4-d]pyrimidine exhibiting selectivity for Lck compared with previously reported compounds. It is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling. It is currently in the preclinical developlent stage and no clinical data are available.
Molecular Weight:
621.73
Molecular Formula:
C34H39N9O3
COA:
Inquire
MSDS:
Inquire
Targets:
Src
Chemical Structure
CAS 869748-10-7 A-770041

Related Src Products


CAS 518058-84-9 KX1-004

KX1-004
(CAS: 518058-84-9)

KX1-004 is an Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. KX1-004 has been used to protect the...

CAS 867331-64-4 TG 100572 Hydrochloride

TG 100572 Hydrochloride
(CAS: 867331-64-4)

TG 100572 is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases for VEGFR1/VEGFR2/FGFR1/Src/Fy...

CAS 330161-87-0 SU6656

SU6656
(CAS: 330161-87-0)

SU6656 is a Src family kinase inhibitor developed by the biotechnology company SUGEN Inc (a subsidiary of Pharmacia) in 2000. SU6656 was initially identified as...

CAS 869748-10-7 A-770041

A-770041
(CAS: 869748-10-7)

A-770041 is an selective and orally bioavailable pyrazolo[3,4-d]pyrimidine exhibiting selectivity for Lck compared with previously reported compounds. It is 300...

CAS 1435934-25-0 A 419259 trihydrochloride

A 419259 trihydrochloride
(CAS: 1435934-25-0)

Potent Hck inhibitor (IC50 = 0.43 nM). Also inhibits other Src family kinases (SFKs). Suppresses proliferation and induces apoptosis in CML cell lines including...

CAS 221243-82-9 1-NA-PP1

1-NA-PP1
(CAS: 221243-82-9)

CAS 364042-47-7 A 419259

A 419259
(CAS: 364042-47-7)

A-419259 is a potent inhibitor of Src family kinases. IC50 values for src, lck, blk, csk, fyn and lyn range between 15 and 50 nM.

HG-9-91-01
(CAS: 1456858-58-4)

HG-9-91-01,a small molecule inhibitor that targets specificly salt-inducible kinase (SIKs) IC50: SIK1=0.92 nM; SIK2=6.6 nM; SIK3=9.6 nM

CAS 172889-27-9 PP2

PP2
(CAS: 172889-27-9)

CAS 837422-57-8 WH-4-023

WH-4-023
(CAS: 837422-57-8)

WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively. The lymphocyte-specific kinase (Lck) is a ...

CAS 867334-05-2 TG 100572

TG 100572
(CAS: 867334-05-2)

TG 100572 is a multi-targeted kinase inhibitor that inhibits select growth factor receptor tyrosine kinases and Src familt kinases.

eCF506
(CAS: 1914078-41-3)

eCF506 is a potent and highl selective inhibitor towards Src tyrosine kinase with a 1000-fold selectivity over ABL. eCF506 inhibits SRC at subnanomolar concentr...

AP-22408
(CAS: 268741-43-1)

AP-22408, a Src tyrosine kinase inhibitor, is an orally bioavailable phosphotyrosine mimic resulting from a structurebased design.

CGP 77675
(CAS: 234772-64-6)

CGP 77675 selectively inhibited phosphorylation of peptide substrates and autophosphorylation of purified Src (IC50: 5-20 and 40 nM, respectively).

CAS 944795-06-6 Lck inhibitor 2

Lck inhibitor 2
(CAS: 944795-06-6)

Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. It inhibited 48 kinases with control less than 1...

CAS 847950-09-8 Lck Inhibitor

Lck Inhibitor
(CAS: 847950-09-8)

Lck Inhibitor is a small-molecule inhibitor. It takes participate in the T-cell receptor (TCR) signal transduction and affects the expression of genes associate...

CAS 897016-82-9 KX2-391

KX2-391
(CAS: 897016-82-9)

KX2-391 is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to t...

CHMFL-ABL-053
(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 221244-14-0 1-NM-PP1

1-NM-PP1
(CAS: 221244-14-0)

1-Naphthyl PP1 hydrochloride
(CAS: 956025-47-1)

1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases, including v-Src and c-Fyn, tyrosine kinase c-Abl and CAMK II with IC50 values of 1....

Reference Reading


1.Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
Burchat A1, Borhani DW, Calderwood DJ, Hirst GC, Li B, Stachlewitz RF. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22. Epub 2005 Oct 10.
We describe the identification, SAR, and pharmacology of the src-family selective lck inhibitor A-770041 that prolongs the survival of major histocompatibility mismatched allografts in models of solid organ transplant rejection for greater than 65 days.
2.A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection.
Stachlewitz RF1, Hart MA, Bettencourt B, Kebede T, Schwartz A, Ratnofsky SE, Calderwood DJ, Waegell WO, Hirst GC. J Pharmacol Exp Ther. 2005 Oct;315(1):36-41. Epub 2005 Jul 12.
Lck, one of eight members of the Src family of tyrosine kinases, is activated after T cell stimulation and is required for T-cell proliferation and interleukin (IL)-2 production. Inhibition of Lck has been a target to prevent lymphocyte activation and acute rejection. Here, we report the pharmacologic characterization of 1-methyl-1H-indole-2-carboxylic acid (4-{1-[4-(4-acetyl-piperazin-l-yl)-cyclohexyl]-4-amino-1H-pyrazolo[3,4-d]pyrimidin-3-yl}-2-methoxy-phenyl)-amide (A-770041), an orally bioavailable pyrazolo[3,4-d]pyrimidine with increased selectivity for Lck compared with previously reported compounds. A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling. Concanavalin A-stimulated IL-2 production in whole blood is inhibited by A-770041 with an EC50 of approximately 80 nM. A-770041 is orally bioavailable (F = 34.1 +/- 7.2% at 10 mg/kg) and has a t(1/2) of 4.
3.A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Duan Z1, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. BMC Cancer. 2014 Sep 19;14:681. doi: 10.1186/1471-2407-14-681.
BACKGROUND: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR by targeting ATP-binding cassette (ABC) transporters (Pgp, MRP) directly, but these efforts have achieved little clinical success. Protein kinases play important roles in many aspects of tumor cell growth and survival. Combinations of kinase inhibitors and chemotherapeutics have been observed to overcome cancer drug resistance in certain circumstances.